1 |
Evans SJ, Waller PC, Davis S. Use of proportional reporting ratios (PRRs) for signal generation from spontaneous adverse drug reaction reports. Pharmacoepidem Drug Saf 2001;10(6):483-6.
DOI
|
2 |
Egberts AC, Meyboom RH, van Puijenbroek EP. Use of measures of disproportionality in pharmacovigilance: three Dutch examples. Drug Saf 2002;25(6):453-8.
DOI
|
3 |
Kim M-S, You S-H, Park HM, et al. Patterns of spontaneous adverse events reporting on human papillomavirus vaccines according to the applicability of Brighton Collaboration Criteria in Korea from 2008 to 2017. Korean J Clin Pharm 2020;30(1):19-30.
DOI
|
4 |
Baig MS, Kolasa-Wolosiuk A, Pilutin A, et al. Finasteride-induced inhibition of 5alpha-reductase type 2 could lead to kidney damage-animal, experimental study. Int J Environ Res Public Health 2019;16(10):1726.
DOI
|
5 |
Irwig MS. Depressive symptoms and suicidal thoughts among former users of finasteride with persistent sexual side effects. J Clin Psychiatry 2012;73(9):1220-3.
DOI
|
6 |
Steers WD. 5alpha-reductase activity in the prostate. Urology 2001;58(6 Suppl 1):17-24.
DOI
|
7 |
Nguyen DD, Marchese M, Cone EB, et al. Investigation of suicidality and psychological adverse events in patients treated with finasteride. JAMA Dermatol 2021;157(1):35-42.
DOI
|
8 |
World Health Organization (WHO). VigiAccessTM. Available from http://www.vigiaccess.org. Accessed August 31, 2021.
|
9 |
Sica DA. Minoxidil: an underused vasodilator for resistant or severe hypertension. J Clin Hypertens (Greenwich) 2004;6(5):283-7.
DOI
|
10 |
Melcangi RC, Caruso D, Abbiati F, et al. Neuroactive steroid levels are modified in cerebrospinal fluid and plasma of post-finasteride patients showing persistent sexual side effects and anxious/depressive symptomatology. J Sex Med 2013;10(10):2598-603.
DOI
|
11 |
Messenger AG, Rundegren J. Minoxidil: mechanisms of action on hair growth. Br J Dermatol 2004;150(2):186-94.
DOI
|
12 |
Marks LS, Gittelman MC, Hill LA, Volinn W, Hoel G. Rapid efficacy of the highly selective alpha(1A)-adrenoceptor antagonist silodosin in men with signs and symptoms of benign prostatic hyperplasia: pooled results of 2 phase 3 studies. J Urol 2013;189(1 Suppl):S122-8.
|
13 |
Lindquist M, Stahl M, Bate A, Edwards IR, Meyboom RH. A retrospective evaluation of a data mining approach to aid finding new adverse drug reaction signals in the WHO international database. Drug Saf 2000;23(6):533-42.
DOI
|
14 |
Traish AM. Health risks associated with long-term finasteride and dutasteride use: it's time to sound the alarm. World J Mens Health 2020;38(3):323-37.
DOI
|